靶向铁死亡治疗非酒精性脂肪性肝病的研究进展

doi:10.16352/j.issn.1001-6325.2023.08.1317

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (8): 1317-1321.doi: 10.16352/j.issn.1001-6325.2023.08.1317

靶向铁死亡治疗非酒精性脂肪性肝病的研究进展

郝丹丹^1*, 张垒², 白春英³

赤峰学院 1.医学部基础医学院生理学教研室;
2.附属医院神经外科;
3.医学部内蒙古人类遗传病研究重点实验室, 内蒙古赤峰 024000

收稿日期:2022-10-13 修回日期:2023-04-10 出版日期:2023-08-05 发布日期:2023-07-26
通讯作者: ^*hdd2011yx@163.com
基金资助:
国家自然科学基金(81860496);内蒙古自然科学基金(2022MS08032)

Research progress of drugs targeting ferroptosis for the treatment of non-alcoholic fatty liver disease

HAO Dandan^1*, ZHANG Lei², BAI Chunying³

1. Department of Physiology, School of Basic Medical Science;
2. Department of Neurosurgery, the Affiliated Hospital;
3. Key Laboratory of Human Genetic Diseases in Inner Mongolia, School of Basic Medical Science, Chifeng University, Chifeng 024000, China

Received:2022-10-13 Revised:2023-04-10 Online:2023-08-05 Published:2023-07-26
Contact: ^*hdd2011yx@163.com

摘要/Abstract

摘要： 铁死亡是一种铁依赖性的调节性细胞死亡形式,铁死亡通过铁过载、GPX4失活和脂质过氧化参与非酒精性脂肪性肝病(NAFLD)发病机制,药物靶向性抑制铁死亡可以缓解NAFLD的进展。抑制铁死亡有望成为治疗NAFLD的潜在新策略。

关键词: 非酒精性脂肪性肝病(NAFLD), 非酒精性脂肪性肝炎(NASH), 铁死亡, 铁死亡抑制剂

Abstract: Emerging evidence indicates that ferroptosis, an iron-dependent form of regulated cell death, plays a critical role in the pathological progression of non-alcoholic fatty liver disease (NAFLD). Ferroptosis involves in the pathogenesis of NAFLD and drugs targeting at ferroptosis by its inhibitors can alleviate the progression of NAFLD both in vitro and in vivo. Pharmacological inhibition of ferroptosis might be a potential strategy of NAFLD treatment.

Key words: non-alcoholic fatty liver disease(NAFLD), non-alcoholic steatohepatitis(NASH), ferroptosis, ferroptosis inhibitor

中图分类号:

R575.5

郝丹丹, 张垒, 白春英. 靶向铁死亡治疗非酒精性脂肪性肝病的研究进展[J]. 基础医学与临床, 2023, 43(8): 1317-1321.

HAO Dandan, ZHANG Lei, BAI Chunying. Research progress of drugs targeting ferroptosis for the treatment of non-alcoholic fatty liver disease[J]. Basic & Clinical Medicine, 2023, 43(8): 1317-1321.

参考文献 25

[1]	Yip TC, Lee HW, Chan WK, et al. Asian perspective on NAFLD-associated HCC[J]. J Hepatol, 2022,76:726-734.
[2]	Stockwell BR. Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications[J]. Cell, 2022,185:2401-2421.
[3]	Kowdley KV, Belt P, Wilson LA, et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease[J]. Hepatology, 2012,55:77-85.
[4]	Yang Z, Wu J, Li X, et al. Association between dietary iron intake and the prevalence of nonalcoholic fatty liver disease: A cross-sectional study[J]. Medicine (Baltimore), 2019,98:e17613. doi:10.1097/MD.0000000000017613.
[5]	Beaton MD, Chakrabarti S, Levstik M, et al. Phase Ⅱ clinical trial of phlebotomy for non-alcoholic fatty liver disease[J]. Aliment Pharmacol Ther, 2013,37:720-729.
[6]	Bonkovsky HL, Jawaid Q, Tortorelli K, et al. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis[J]. J Hepatol, 1999,31:421-429.
[7]	Nelson JE, Wilson L, Brunt EM, et al. Relationship between the pattern of hepatic iron deposition and histolo-gical severity in nonalcoholic fatty liver disease[J]. Hepatology, 2011,53:448-457.
[8]	Tsurusaki S, Tsuchiya Y, Koumura T, et al. Hepatic ferroptosis plays an important role as the trigger for initiating inflammation in nonalcoholic steatohepatitis[J]. Cell Death Dis, 2019,10:449. doi:10.1038/s41419-019-1678-y.
[9]	Protchenko O, Baratz E, Jadhav S, et al. Iron chaperone poly rC binding protein 1 protects mouse liver from lipid peroxidation and steatosis[J]. Hepatology, 2021,73:1176-1193.
[10]	Yang Y, Chen J, Gao Q, et al. Study on the attenuated effect of Ginkgolide B on ferroptosis in high fat diet induced nonalcoholic fatty liver disease[J]. Toxicology, 2020,445:152599. doi:10.1016/j.tox.2020.152599.
[11]	Gao G, Xie Z, Li EW, et al. Dehydroabietic acid improves nonalcoholic fatty liver disease through activating the Keap1/Nrf2-ARE signaling pathway to reduce ferroptosis[J]. J Nat Med, 2021,75:540-552.
[12]	Li X, Wang TX, Huang X, et al. Targeting ferroptosis alleviates methionine-choline deficient (MCD)-diet induced NASH by suppressing liver lipotoxicity[J]. Liver Int, 2020,40:1378-1394.
[13]	Gao H, Jin Z, Bandyopadhyay G, et al. Aberrant iron distribution via hepatocyte-stellate cell axis drives liver lipogenesis and fibrosis[J]. Cell Metab, 2022,34:1201-1213.e5.
[14]	Qi J, Kim JW, Zhou Z, et al. Ferroptosis affects the progression of nonalcoholic steatohepatitis via the modulation of lipid peroxidation-mediated cell death in mice[J]. Am J Pathol, 2020,190:68-81.
[15]	Carlson BA, Tobe R, Yefremova E, et al. Glutathione peroxidase 4 and vitamin E cooperatively prevent hepatocellular degeneration[J]. Redox Biol, 2016,9:22-31.
[16]	Sztolsztener K, Chabowski A, Harasim-Symbor E, et al. Arachidonic acid as an early indicator of inflammation during non-alcoholic fatty liver disease development[J]. Biomolecules, 2020,10:1133. doi:10.3390/biom10081133.
[17]	Kim EH, Wong SW, Martinez J. Programmed necrosis and disease:We interrupt your regular programming to bring you necroinflammation[J]. Cell Death Differ, 2019,26:25-40.
[18]	Bailey AP, Koster G, Guillermier C, et al. Antioxidant role for lipid droplets in a stem cell niche of drosophila[J]. Cell, 2015,163:340-353.
[19]	Wei S, Qiu T, Wang N, et al. Ferroptosis mediated by the interaction between Mfn2 and IREα promotes arsenic-induced nonalcoholic steatohepatitis[J]. Environ Res, 2020,188:109824. doi:10.1016/j.envres.2020.109824.
[20]	Zhu Z, Zhang Y, Huang X, et al. Thymosin beta 4 alleviates non-alcoholic fatty liver by inhibiting ferroptosis via up-regulation of GPX4[J]. Eur J Pharmacol, 2021,908:174351. doi:10.1016/j.ejphar.2021.174351.
[21]	Saryusz-Wolska M, Szymańska-Garbacz E, Jabłkowski M, et al. Rosiglitazone treatment in nondiabetic subjects with nonalcoholic fatty liver disease[J]. Pol Arch Med Wewn, 2011,121:61-66.
[22]	Kung YA, Chiang HJ, Li ML, et al. Acyl-coenzyme a synthetase long-chain family member 4 is involved in viral replication organelle formation and facilitates virus replication via ferroptosis[J]. mBio, 2022,13:e0271721. doi:10.1128/mbio.02717-21.
[23]	Ma K, Chen Y, Liang X, et al. Inhibition of 5-lipoxygenase inhibitor zileuton in high-fat diet-induced nonalcoholic fatty liver disease progression model[J]. Iran J Basic Med Sci, 2017,20:1207-1212.
[24]	Jiang JJ, Zhang GF, Zheng JY, et al. Targeting mitochondrial ROS-mediated ferroptosis by quercetin alleviates high-fat diet-induced hepatic lipotoxicity[J]. Front Pharmacol, 2022,13:876550. doi:10.3389/fphar.2022.876550.
[25]	Ning K, Lu K, Chen Q, et al. Epigallocatechin gallate protects mice against methionine-choline-deficient-diet-induced nonalcoholic steatohepatitis by improving gut microbiota to attenuate hepatic injury and regulate metabolism[J]. ACS Omega, 2020,5:20800-20809.

靶向铁死亡治疗非酒精性脂肪性肝病的研究进展

Research progress of drugs targeting ferroptosis for the treatment of non-alcoholic fatty liver disease

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 25

相关文章 14

编辑推荐

Metrics

本文评价

[1]	肖艳红, 姜明东, 林叶远, 冉灿, 梁博. 灯盏花乙素抑制人前列腺癌细胞系PC-3的增殖和迁移[J]. 基础医学与临床, 2024, 44(9): 1229-1235.
[2]	肖艳新, 刘岩, 许岭翎, 周亚茹. 铁死亡在非酒精性脂肪性肝病发病中作用的研究进展[J]. 基础医学与临床, 2024, 44(2): 260-264.
[3]	田宗源, 李展, 刘瑞霞. TERT调控线粒体氧化应激在疾病中的作用[J]. 基础医学与临床, 2024, 44(10): 1436-1441.
[4]	孙立杰, 郝丹丹. 诱导肝星状细胞铁死亡治疗肝纤维化的研究进展[J]. 基础医学与临床, 2024, 44(1): 108-113.
[5]	李想, 李晔. 非酒精性脂肪性肝病中自噬与铁死亡相互作用的研究进展[J]. 基础医学与临床, 2023, 43(8): 1294-1298.
[6]	楚晓云, 蔡成. 铁死亡在新生儿急性肺损伤中作用机制的研究进展[J]. 基础医学与临床, 2023, 43(6): 1008-1011.
[7]	闫霖, 陆珏秀, 罗颖, 刘先霞. BM-MSCs来源外泌体介导铁死亡减轻大鼠心肌细胞系H9c2缺氧/复氧损伤[J]. 基础医学与临床, 2023, 43(5): 771-776.
[8]	向彩霞, 黄彬涛, 郝建. 抗凋亡抑制剂维奈克拉在治疗髓系白血病的研究进展[J]. 基础医学与临床, 2023, 43(5): 833-836.
[9]	曲大鹏, 孙会艳, 李强, 王洪权. 铁死亡在蛛网膜下腔出血早期脑损伤发病机制中作用的研究进展[J]. 基础医学与临床, 2023, 43(3): 486-489.
[10]	庄志诚, 官国先. 铁死亡在结直肠癌治疗中的作用[J]. 基础医学与临床, 2023, 43(1): 174-177.
[11]	薛晋芳, 宋海飞, 陈国兵. 程序性细胞死亡在脓毒症发生发展中的研究进展[J]. 基础医学与临床, 2022, 42(8): 1284-1287.
[12]	徐娟, 李晔. 铁死亡在阿尔茨海默病中作用的研究进展[J]. 基础医学与临床, 2022, 42(7): 1129-1133.
[13]	王冯宇, 李亘, 林晓伊, 姚欣悦, 陈毓. 铁死亡在肿瘤治疗作用中的研究进展[J]. 基础医学与临床, 2022, 42(11): 1781-1784.
[14]	徐飞, 陈维达, 郭溟浩, 陈泽涛. 铁死亡调控机制及在肺癌治疗中的研究进展[J]. 基础医学与临床, 2021, 41(3): 442-447.